US equities
|
MU
$1,049.08
▼-3.58%
NVDA
$231.01
▼-2.72%
SNDK
$1,620.43
▼-4.25%
AMD
$619.35
▼-4.11%
INTC
$106.60
▼-5.76%
SPCX
$162.23
▼-3.20%
META
$718.99
▼-0.32%
PLTR
$197.53
▲+1.75%
MU
$1,049.08
▼-3.58%
NVDA
$231.01
▼-2.72%
SNDK
$1,620.43
▼-4.25%
AMD
$619.35
▼-4.11%
INTC
$106.60
▼-5.76%
SPCX
$162.23
▼-3.20%
META
$718.99
▼-0.32%
PLTR
$197.53
▲+1.75%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
CNS Pharmaceuticals, Inc. - Common Stock
(NQ:
CNSP
)
5.350
-0.080 (-1.47%)
Delayed Quote
Updated: 12:56 PM EDT, Oct 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about CNS Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
...
18
19
20
21
22
23
24
25
Next >
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
↗
April 19, 2022
Good morning! It's time to start off another busy day of trading with a dive into the biggest pre-market stock movers for Tuesday!
Via
InvestorPlace
JTC Team Announces Continuation of its Virtual Investor Spotlight Series with NASDAQ: AEZS, NASDAQ: CNSP, and NASDAQ: AREC
April 13, 2022
- Live video webcast events on Thursday, April 14 at 10 AM ET, 11:30 AM ET and 1 PM ET - FRENCHTOWN, NJ / ACCESSWIRE / April 13, 2022 / JTC Team ("JTC"), a fully integrated corporate communications and...
From
JTC Team, LLC
Via
AccessWire
European Regulatory Approvals Help CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Advance ‘Potentially Pivotal’ Study of Novel Brain Cancer Drug
April 13, 2022
Via
Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) To Participate In Upcoming Virtual Investor Event
↗
April 12, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via
Benzinga
CNS Pharmaceuticals (NASDAQ: CNSP) to Participate in Upcoming Virtual Investor Event
April 12, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Participate in Upcoming Virtual Investor Event
April 12, 2022
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Leading the Charge toward Advancing Research on Treatments for Primary and Metastatic Central Nervous System Cancers
April 11, 2022
Via
Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) Receives Key Approval for Pivotal Study of Berubicin
↗
April 06, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via
Benzinga
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures Approval from France EC and ANSM Competent Authority for Potentially Pivotal Study of Berubicin
April 06, 2022
Via
Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) Receives Key Approval for Pivotal Study of Berubicin
April 06, 2022
Via
Investor Brand Network
51 Biggest Movers From Yesterday
↗
April 06, 2022
Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) shares surged 148.2% to close at $5.61 on Tuesday after the company announced that two of its designed mRNA molecules are...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
April 05, 2022
Gainers Sunshine Biopharma (NASDAQ:SBFM) shares rose 141.5% to $5.46 during Tuesday's regular session. Trading volume for this security as of 13:30 EST is 114.7...
Via
Benzinga
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Receives Key Approval for Pivotal Study of Berubicin
April 05, 2022
Via
Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) CEO Shares Company Highlights At Virtual Growth Conference
↗
April 05, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. The three-day event showcased CNS...
Via
Benzinga
CNS Pharmaceuticals (NASDAQ: CNSP) CEO Shares Company Highlights at Virtual Growth Conference
April 05, 2022
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) CEO John Climaco Shares Company Highlights, Goals at 2022 Virtual Growth Conference Presented by Maxim Group LLC
April 04, 2022
Via
Investor Brand Network
CNS Pharmaceuticals To Participate At 2022 Virtual Growth Conference
↗
March 24, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via
Benzinga
CNS Pharmaceuticals (NASDAQ: CNSP) to Participate at 2022 Virtual Growth Conference
March 24, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Participate at the 2022 Virtual Growth Conference
March 23, 2022
Via
Investor Brand Network
CNS Pharmaceuticals CEO Discusses Milestone In Advancing Berubicin
↗
March 18, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via
Benzinga
CNS Pharmaceuticals (NASDAQ: CNSP) CEO Discusses Milestone in Advancing Berubicin
March 18, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Discusses Significant Milestone in Advancing Berubicin
March 17, 2022
Via
Investor Brand Network
95 Biggest Movers From Friday
↗
March 14, 2022
Gainers Marygold Companies (NYSE: MGLD) shares surged 89.4% to close at $4.11 on Friday after dropping 21% on Thursday. TeraWulf Inc. (NASDAQ: WULF) gained 49.3% to close at $9....
Via
Benzinga
CNS Pharmaceuticals Reiterates Progress For Lead Product Candidate
↗
March 10, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. CNS Pharmaceuticals (NASDAQ: CNSP),...
Via
Benzinga
CNS Pharmaceuticals (NASDAQ: CNSP) Reiterates Progress for Lead Product Candidate
March 10, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reiterates Progress for Lead Product Candidate, Addresses Recent Share Price Activity in Video to Shareholders
March 09, 2022
Via
Investor Brand Network
CNS Pharmaceuticals Gives Corporate Presentation, Q&A Session
↗
March 08, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. CNS Pharmaceuticals recently received...
Via
Benzinga
CNS Pharmaceuticals (NASDAQ: CNSP) Gives Corporate Presentation, Q&A Session
March 08, 2022
Via
Investor Brand Network
12 Health Care Stocks Moving In Monday's After-Market Session
↗
March 07, 2022
Gainers
Via
Benzinga
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Gives Corporate Presentation, Q&A Session at Virtual Investor 2022 Top Picks Conference
March 07, 2022
Via
Investor Brand Network
< Previous
1
2
...
18
19
20
21
22
23
24
25
Next >
